Dexcom Expands Stelo Glucose Biosensor to Pediatric Use, Launches Redesigned App
Event summary
- Dexcom received FDA clearance to expand Stelo Glucose Biosensor use to children aged 2+ not using insulin.
- Stelo app redesign launches in July 2026 for US iPhone and Android users.
- International rollout planned for UK, Australia, New Zealand, and South Korea starting late 2026.
- Pediatric clearance addresses rising youth Type 2 diabetes rates (4.5% prevalence under 18 in US).
The big picture
Dexcom's expansion into pediatric use and international markets positions it as a leader in preventive biosensing technology. The company is capitalizing on rising metabolic health awareness while addressing critical gaps in youth diabetes management. With Type 2 diabetes cases among children projected to increase by 700%, Dexcom's strategic moves could significantly impact both public health outcomes and its own market position.
What we're watching
- Market Expansion Pace
- Whether Dexcom can successfully execute its international rollout timeline across four countries by 2027.
- Pediatric Adoption
- How quickly pediatric users and caregivers will embrace the Stelo biosensor given rising youth diabetes rates.
- Competitive Response
- Whether competitors will accelerate their own non-prescription glucose monitoring solutions in response to Dexcom's moves.